Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
Radiation oncology is used as an adjuvant therapy to other modalities of treatment (and in some cases, it can even be used as a neoadjuvant
Mesothelioma’s presentation makes it difficult to identify the cancer through imaging techniques; however, certain methods are better than others. Sometimes, the combination of two methods
In recent years, much of cancer research has been driven by new and novel therapies. These therapies include t-cell therapies and precision medicine. When undergoing
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
